NCT02081378 2024-03-18
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
Phase 1 Completed
Novartis
Fred Hutchinson Cancer Center
Novartis
H. Lee Moffitt Cancer Center and Research Institute
Sarcoma Alliance for Research through Collaboration